After 13 years at the helm of the UK’s BioIndustry Association, Steve Bates has tendered his resignation as chief executive ...

Cambridge, USA-based biotech Avalyn Pharma, which developing inhaled therapies for the treatment of life-threatening pulmonary diseases, has announced the closing of an oversubscribed $100 million ...

French pharma Ipsen (Euronext: IPN) today announced the following changes to its executive committee: Mari Scheiffele is appointed executive vice president (EVP) , chief product officer, Andreas ...

Patients in the UK will now be able to access advanced, personalized treatments prepared at the hospital or even in mobile ...

Swiss pharma Sandoz (SIX: SDZ) has spent less than a year charting its course as an independent company, but already it’s ...

Shares in Replimune Group, a US biotech developing novel oncolytic immunotherapies, went in freefall Tuesday, as the company ...

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Shares in Sarepta Therapeutics have slumped by more than a third since late last week amid new updates on its gene therapy ...

French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

US biotech iTeos Therapeutics yesterday announced that it has entered into a definitive merger agreement Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, this year, ...

Neuraxpharm Group, a privately-held German specialty pharma focused on central nervous system (CNS) disorders, today announced the launch of a new affiliate, Neuraxpharm Australia, led by newly ...

Canadian biotech Eyam Health has entered a research alliance with Swiss-based nonprofit Medicines for Malaria Venture to ...